Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.
The future for Novo Nordisk A/S’s obesity drug in the Medicare Part D market is getting more complicated. Even if efforts by the company and patient advocates manage to change the law to allow for coverage of Wegovy in Part D, it could face significant price controls once it gets there.
Drugs with obesity as their primary indication are currently excluded from Part D coverage, a prohibition that goes back to the Medicare Modernization Act of 2003, based in part on the perception at
European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.
Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.
